Arthur He
Stock Analyst at HC Wainwright & Co.
(4.20)
# 488
Out of 4,712 analysts
62
Total ratings
38.33%
Success rate
26.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LVTX LAVA Therapeutics | Maintains: Buy | $6 → $2 | $0.99 | +101.61% | 8 | Dec 20, 2024 | |
| SLDB Solid Biosciences | Reiterates: Buy | $16 | $4.37 | +266.13% | 6 | Dec 12, 2024 | |
| PSTX Poseida Therapeutics | Downgrades: Neutral | $20 → $9 | $9.51 | -5.36% | 17 | Nov 26, 2024 | |
| ADAP Adaptimmune Therapeutics | Reiterates: Buy | $3.5 | $0.57 | +516.52% | 5 | Nov 19, 2024 | |
| BCAB BioAtla | Downgrades: Neutral | n/a | $0.64 | - | 7 | Nov 13, 2024 | |
| PRME Prime Medicine | Reiterates: Buy | $10 | $2.94 | +240.14% | 5 | Nov 13, 2024 | |
| ADAG Adagene | Reiterates: Buy | $5 | $1.96 | +155.10% | 8 | Sep 18, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Buy | $50 → $60 | $1.85 | +3,143.24% | 6 | Jun 5, 2024 |
LAVA Therapeutics
Dec 20, 2024
Maintains: Buy
Price Target: $6 → $2
Current: $0.99
Upside: +101.61%
Solid Biosciences
Dec 12, 2024
Reiterates: Buy
Price Target: $16
Current: $4.37
Upside: +266.13%
Poseida Therapeutics
Nov 26, 2024
Downgrades: Neutral
Price Target: $20 → $9
Current: $9.51
Upside: -5.36%
Adaptimmune Therapeutics
Nov 19, 2024
Reiterates: Buy
Price Target: $3.5
Current: $0.57
Upside: +516.52%
BioAtla
Nov 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.64
Upside: -
Prime Medicine
Nov 13, 2024
Reiterates: Buy
Price Target: $10
Current: $2.94
Upside: +240.14%
Adagene
Sep 18, 2024
Reiterates: Buy
Price Target: $5
Current: $1.96
Upside: +155.10%
HOOKIPA Pharma
Jun 5, 2024
Maintains: Buy
Price Target: $50 → $60
Current: $1.85
Upside: +3,143.24%